INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 143 filers reported holding INFINITY PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 2.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $251,000 | -13.4% | 185,871 | 0.0% | 0.00% | – |
| Q3 2016 | $290,000 | +16.9% | 185,871 | -0.4% | 0.00% | – |
| Q2 2016 | $248,000 | -73.2% | 186,575 | +6.0% | 0.00% | -100.0% |
| Q1 2016 | $927,000 | -32.2% | 175,980 | +1.1% | 0.00% | -50.0% |
| Q4 2015 | $1,367,000 | -6.4% | 174,092 | +0.8% | 0.00% | 0.0% |
| Q3 2015 | $1,460,000 | -23.4% | 172,757 | -0.7% | 0.00% | 0.0% |
| Q2 2015 | $1,905,000 | -3.9% | 173,975 | +22.7% | 0.00% | -33.3% |
| Q1 2015 | $1,982,000 | -16.3% | 141,774 | +1.2% | 0.00% | 0.0% |
| Q4 2014 | $2,367,000 | +25.2% | 140,131 | -0.5% | 0.00% | 0.0% |
| Q3 2014 | $1,890,000 | +5.4% | 140,853 | +0.0% | 0.00% | +50.0% |
| Q2 2014 | $1,794,000 | +13.6% | 140,791 | +6.0% | 0.00% | 0.0% |
| Q1 2014 | $1,579,000 | -13.4% | 132,780 | +0.6% | 0.00% | -33.3% |
| Q4 2013 | $1,823,000 | -22.4% | 131,993 | -2.1% | 0.00% | -25.0% |
| Q3 2013 | $2,350,000 | +14.8% | 134,826 | +6.6% | 0.00% | 0.0% |
| Q2 2013 | $2,047,000 | – | 126,432 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |